Structural Formula (Image 01)
Chemical structure diagram of fosaprepitant, showing its molecular components and bonding arrangement.*
Fosaprepitant Injection, Powder, Lyophilized, For Solution
Product Images NDC 67457-889
6 FDA label images from Mylan Institutional Llc · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Fosaprepitant (NDC 67457-889). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Mylan Institutional Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Image 02)
A line graph showing the mean plasma concentration of aprepitant (ng/mL) over time (hours) following administration of 125 mg oral aprepitant and 115 mg intravenous fosaprepitant. The graph compares plasma levels over a 72-hour period, illustrating concentration changes for both oral and IV routes.*
Figure 2 (Image 03)
A figure titled 'Percent of Patients Receiving Highly Emetogenic Chemotherapy Who Remain Emesis Free Over Time - Cycle 1' showing two line graphs from Study 1 and Study 2. The y-axis represents percent of patients and the x-axis represents hours up to 120. Each study compares an Aprepitant Regimen group and a Standard Therapy group, with the Aprepitant group maintaining higher emesis-free percentages over time in both studies.*
Figure 3 (Image 04)
A bar graph showing the proportion of patients receiving highly emetogenic chemotherapy with no emesis and no significant nausea by treatment group and chemotherapy cycle. The graph compares Aprepitant Regimen versus Standard Therapy across cycles 2 to 6 in two studies, displaying percent of patients on the vertical axis and chemotherapy cycle number on the horizontal axis. Patient counts for each group and cycle are listed below the graph.*
115 mg-carton (Image 05)
Packaging label for Fosaprepitant for Injection 115 mg per vial, sterile lyophilized powder. Intended for intravenous use only after reconstitution and dilution. Manufactured for Mylan Institutional LLC, Rockford, IL. The label includes storage instructions, dilution and preparation details, and a warning against using with solutions containing divalent cations. The vial is marked as Rx only and single-dose.*
Carton-150 mg (Image 06)
Packaging label for Fosaprepitant for Injection, sterile lyophilized powder, 150 mg per vial, for intravenous use. The label includes instructions to reconstitute with 5 mL of 0.9% Sodium Chloride for Injection and warnings about use with divalent cations. It is manufactured for Mylan Institutional LLC and includes storage instructions to refrigerate at 2°C to 8°C. The label features the NDC number 67457-889-10 and the Mylan logo.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
